Publicaciones en colaboración con investigadores/as de Hospital Clínico San Carlos de Madrid (12)

2022

  1. Clinical characteristics, health care resource utilization and direct medical costs of Rotavirus hospitalizations in Spain (2013–2018)

    Human Vaccines and Immunotherapeutics, Vol. 18, Núm. 5

2021

  1. Rotavirus gastroenteritis hospitalizations in provinces with different vaccination coverage rates in Spain, 2013–2018

    BMC Infectious Diseases, Vol. 21, Núm. 1

2019

  1. Clinical practice update of antifungal prophylaxis in immunocompromised children

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 5, pp. 410-425

2013

  1. Expansion of serotype coverage in the universal pediatric vaccination calendar: Short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain

    Clinical and Vaccine Immunology, Vol. 20, Núm. 10, pp. 1524-1530

  2. Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011

    Pediatric Infectious Disease Journal

2012

  1. Five-year antibody persistence and safety following a booster dose of combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine

    Pediatric Infectious Disease Journal, Vol. 31, Núm. 10, pp. 1074-1077

2011

  1. Clonal and clinical profile of Streptococcus pneumoniae serotype 19A causing pediatric invasive infections: A 2-year (2007-2009) laboratory-based surveillance in Madrid

    Vaccine, Vol. 29, Núm. 9, pp. 1770-1776

  2. Laboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in madrid

    Pediatric Infectious Disease Journal, Vol. 30, Núm. 6, pp. 471-474

  3. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar

    Clinical and Vaccine Immunology, Vol. 18, Núm. 1, pp. 89-94

2008

  1. Immunogenicity and reactogenicity of a booster dose of a novel combined haemophilus influenzae type b-neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age

    Pediatric Infectious Disease Journal, Vol. 27, Núm. 7, pp. 579-588

2007

  1. Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus- acellular pertussis-hepatitis B-inactivated poliovirus vaccine at 2, 4 and 6 months

    Pediatric Infectious Disease Journal, Vol. 26, Núm. 1, pp. 1-7

2006

  1. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine

    Pediatric Infectious Disease Journal, Vol. 25, Núm. 8, pp. 713-720